Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.

Cancer Discov. 2014 Feb;4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639. Epub 2014 Jan 23.

2.

Uncovering metabolism in rhabdomyosarcoma.

Monti E, Fanzani A.

Cell Cycle. 2016;15(2):184-95. doi: 10.1080/15384101.2015.1071746. Review.

3.

A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.

Lynn M, Shah N, Conroy J, Ennis S, Morris T, Betts D, O'Sullivan M.

Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):213-21. doi: 10.1097/PDM.0000000000000030.

PMID:
24614150
4.

Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.

Seki M, Nishimura R, Yoshida K, Shimamura T, Shiraishi Y, Sato Y, Kato M, Chiba K, Tanaka H, Hoshino N, Nagae G, Shiozawa Y, Okuno Y, Hosoi H, Tanaka Y, Okita H, Miyachi M, Souzaki R, Taguchi T, Koh K, Hanada R, Kato K, Nomura Y, Akiyama M, Oka A, Igarashi T, Miyano S, Aburatani H, Hayashi Y, Ogawa S, Takita J.

Nat Commun. 2015 Jul 3;6:7557. doi: 10.1038/ncomms8557.

5.

[Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].

Gao H, Ou YL, Zhang KR, Zhang ZB, Wang WL.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Feb;24(1):42-7. Chinese.

PMID:
17285543
6.

Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.

Sun W, Chatterjee B, Shern JF, Patidar R, Song Y, Wang Y, Walker RL, Pawel BR, Linardic CM, Houghton P, Hewitt SM, Edelman DC, Khan J, Meltzer PS, Barr FG.

Int J Cancer. 2019 Jun 1;144(11):2707-2717. doi: 10.1002/ijc.32006. Epub 2019 Jan 15.

PMID:
30565669
7.

Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.

Teot LA, Schneider M, Thorner AR, Tian J, Chi YY, Ducar M, Lin L, Wlodarski M, Grier HE, Fletcher CDM, van Hummelen P, Skapek SX, Hawkins DS, Wagers AJ, Rodriguez-Galindo C, Hettmer S.

Cancer. 2018 May 1;124(9):1973-1981. doi: 10.1002/cncr.31286. Epub 2018 Feb 20.

8.

Clonality and evolutionary history of rhabdomyosarcoma.

Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J.

PLoS Genet. 2015 Mar 13;11(3):e1005075. doi: 10.1371/journal.pgen.1005075. eCollection 2015 Mar.

9.

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.

Marshall AD, van der Ent MA, Grosveld GC.

Mol Carcinog. 2012 Oct;51(10):807-15. doi: 10.1002/mc.20848. Epub 2011 Aug 31.

PMID:
21882254
10.

Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Böhm M, Wachtel M, Marques JG, Streiff N, Laubscher D, Nanni P, Mamchaoui K, Santoro R, Schäfer BW.

J Clin Invest. 2016 Nov 1;126(11):4237-4249. doi: 10.1172/JCI85057. Epub 2016 Oct 17.

11.

Landscape of genomic alterations in cervical carcinomas.

Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabiño NB, Gómez-Macías GS, Valdez-Chapa LD, Garza-Rodríguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldaña HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M.

Nature. 2014 Feb 20;506(7488):371-5. doi: 10.1038/nature12881. Epub 2013 Dec 25.

12.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

13.

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.

Nguyen TH, Barr FG.

Molecules. 2018 Oct 28;23(11). pii: E2798. doi: 10.3390/molecules23112798. Review.

14.

Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.

de Souza RR, Oliveira ID, Caran EM, Alves MT, Abib S, Toledo SR.

Growth Horm IGF Res. 2012 Dec;22(6):245-9. doi: 10.1016/j.ghir.2012.07.003. Epub 2012 Oct 16.

PMID:
23079386
15.

PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.

Pandey PR, Chatterjee B, Olanich ME, Khan J, Miettinen MM, Hewitt SM, Barr FG.

J Pathol. 2017 Apr;241(5):626-637. doi: 10.1002/path.4867. Epub 2017 Mar 1.

16.

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.

Cancer Res. 2010 Aug 15;70(16):6497-508. doi: 10.1158/0008-5472.CAN-10-0582. Epub 2010 Jul 27.

17.
18.

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.

Hanna JA, Garcia MR, Lardennois A, Leavey PJ, Maglic D, Fagnan A, Go JC, Roach J, Wang YD, Finkelstein D, Hatley ME.

Oncogene. 2018 Apr;37(15):1991-2007. doi: 10.1038/s41388-017-0081-3. Epub 2018 Jan 25.

19.

The genetic landscape of 87 ovarian germ cell tumors.

Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I.

Gynecol Oncol. 2018 Oct;151(1):61-68. doi: 10.1016/j.ygyno.2018.08.013. Epub 2018 Aug 28.

PMID:
30170975
20.

Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.

Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.

Genes Chromosomes Cancer. 2012 Jul;51(7):662-74. doi: 10.1002/gcc.21953. Epub 2012 Mar 23.

Supplemental Content

Support Center